USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: ARMAGEN TECHNOLOGIES, INC.
City: Calabasas
State: CA
Zip+4: -
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: http://www.armagen.com
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $4,465,845.00 16
SBIR Phase II $13,472,906.00 9

Award List:

DRUG DEVELOPMENT OF AN ALZHEIMER'S DISEASE BRAIN SCAN

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jian Y. Li
Award Amount: $112,000.00
Abstract:
DESCRIPTION (provided by applicant):The goal of this work is the development of an Alzheimer' s disease (AD) diagnostic brain scan. AD is caused by the deposition of arnyloid in the brain and a diagnostic brain scan for AD could be developed if amyloid imaging agents were made… More

Drug Development of an Alzheimer's disease brain scan

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $1,358,735.00
Abstract:
DESCRIPTION (provided by applicant): The dementia of Alzheimer's Disease (AD) is caused by the buildup in the brain over many years of amyloid. Therefore, the development of a brain scan that measures brain amyloid could identify those individuals at risk for the later development of AD. Early… More

Neuroprotection in Stroke Drug Development

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): There presently is no neuroprotective agent that can be given to patients with acute stroke. The costs for rehabilitation of patients that survive a stroke are greater than $40 billion per year in the U.S. The reason that an effective neuroprotective drug has not… More

Targeted EGFR Antisense Gene Therapy for Brain Cancer

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $589,796.00
Abstract:
DESCRIPTION (provided by applicant): The incidence of brain cancer in the U.S. is surprisingly high, and includes 15,000 new cases per year of the highly malignant primary brain cancer, glioblastoma multiforme (GBM), and about 150,000 cases per year of metastatic cancer to brain. The epidermal… More

Neuroprotection in Stroke w/ Recombinant Fusion Protein

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $100,000.00
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Stroke is the third leading cause of death and affects nearly 1 million people in the U.S. each year. The cost for rehabilitation of stroke survivors is over $40 billion per year in the U.S. The debilitating effects of stroke derive from the loss of brain cells… More

Imaging Brain Amyloid with a Bispecific Antibody

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yun Zhang
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): The dementia of Alzheimer's Disease (AD) is caused by the slow accumulation of brain amyloid. Therefore, the development of a brain scan that measures brain amyloid could identify those individuals at risk for the later development of AD. Early detection can… More

Neuroprotection in Stroke Drug Development

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $3,727,392.00
Abstract:
DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute stroke, and stroke is the third leading cause of death. The costs for rehabilitation of patients that… More

Stroke neuroprotection with a recombinant fusion protein

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $749,152.00
Abstract:
DESCRIPTION (provided by applicant): Approximately 800,000 persons in the U.S. suffer an acute stroke each year. There presently is no neuroprotective agent that can be given to patients with acute stroke, and stroke is the third leading cause of death. The costs for rehabilitation of patients that… More

Recombinant Enzyme Fusion Protein for Lysosomal Storage

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yun Zhang
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment of the lysosomal storage disorders is enzyme replacement therapy (ERT). However, ERT is not effective for the… More

Targeted Paraoxonase Fusion Protein as a Neurotherapeutic for Nerve Gas Agents

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yufeng Zhang
Award Amount: $1,951,121.00
Abstract:
DESCRIPTION (provided by applicant): Civilian populations are at risk for exposure to chemical nerve gas agents such as organophosphates (OPs). These compounds affect both the peripheral nervous system (PNS) and the central nervous system (CNS). The CNS is affected because the OPs are lipid-soluble… More

Recombinant Enzyme Fusion Protein for Lysosomal Storage Disorders

Award Year / Program / Phase: 2007 / SBIR / Phase II
Agency: HHS
Principal Investigator: Yun Zhang
Award Amount: $813,983.00
Abstract:
DESCRIPTION (provided by applicant): Zhang, Yun Abstract There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is enzyme replacement therapy (ERT). However, ER T is not effective for the brain, because… More

Iduronidase Replacement Therapy of the Brain in Hurler's Syndrome

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is enzyme replacement therapy (ERT). However, ERT is not effective f or the brain, because the enzymes do not… More

Bioengineering of a New Antibody Drug Delivery Technology

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Yun Zhang
Award Amount: $149,050.00
Abstract:
DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow disease, West Nile encephalitis, neuro-AIDS, brain injury, brain cance r, or multiple sclerosis. In almost all… More

Targeted Delivery of siRNA for Intravenous RNAi

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $385,780.00
Abstract:
DESCRIPTION (provided by applicant): RNA interference (RNAi) is a relatively new technology that enables the knockdown of expression of pathologic genes with short interfering RNAs (siRNAs). The limiting factor in the development of new RNAi medicines is d elivery. The goal of the field is … More

Targeted Neurotrophin Drug Development in Parkinson's Disease

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $100,000.00
Abstract:
DESCRIPTION (provided by applicant): Parkinson's disease (PD) is a severe degenerative condition of the brain that affects 1 million people in the U.S. PD is caused by the progressive neurodegeneration of the nigral-striatal tract in brain. The brain produ ces endogenous neurotrophins that protect… More

Bioengineering of a New Decoy Receptor Drug Delivery Technology

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kawai Hui
Award Amount: $111,999.00
Abstract:
DESCRIPTION (provided by applicant): Decoy receptors are potential new pharmaceuticals to treat brain diseases, such as brain injury, spinal cord injury, stroke, or neurodegeneration. However, decoy receptor drugs are large molecule pharmaceuticals that do not cross the blood-brain barrier (BBB).… More

Iduronidase Replacement Therapy of the Brain in Hurler's Syndrome

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado
Award Amount: $2,940,848.00
Abstract:
DESCRIPTION (provided by applicant): Abstract There are over 40 lysosomal storage disorders, and most of these diseases affect adversely the central nervous system (CNS). The mainstay of treatment is enzyme replacement therapy (ERT). However, ERT is not effective for the brain, because the enzymes… More

Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Zhiqiang Lu – 310-917-1275
Award Amount: $111,214.00
Abstract:
DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is an genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Consequently, patients with MPS-II develop extensive lysosomalstorage product accumulation in… More

Re-Engineering Blood-Borne Erythropoietin for Targeted Delivery

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ruben J. Boado – 310-917-1275
Award Amount: $149,800.00
Abstract:
DESCRIPTION (provided by applicant): Erythropoietin (EPO) is a potential new pharmaceutical to treat vascular disease of the brain, including stroke. However, EPO is a large molecule pharmaceutical that does not cross the capillary endothelial wall in brain, which forms the blood-brain barrier… More

Bioengineering of a New Antibody Drug Delivery Technology

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado – 310-917-1275
Award Amount: $849,582.00
Abstract:
DESCRIPTION (provided by applicant): Monoclonal antibodies (MAb) are potential new therapeutics for many brain diseases, including Alzheimer's disease (AD), Parkinson's disease, mad cow disease, West Nile encephalitis, neuro- AIDS, brain injury, brain cancer, or multiple sclerosis. In… More

Enzyme replacement therapy of the brain in Mucopolysaccharidosis Type II

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: Zhiqiang Lu – 310-917-1275
Award Amount: $1,052,435.00
Abstract:
DESCRIPTION (provided by applicant): Type II Mucopolysaccharidosis (MPS), also known as Hunter's syndrome, is a genetic disease that affects the lysosomal enzyme, iduronate-2-sulfatase (IDS). Consequently, patients with MPS-II develop extensive lysosomal storage product accumulation in tissues,… More

Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ruben J. Boado – 310-917-1275
Award Amount: $148,530.00
Abstract:
DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)- plays a pro-inflammatory role in brain diseases. The biologic TNF inhibitors (TNFI), such as the TNF decoy receptor cannot be developed for brain diseases, because the TNFIs are large molecules that do not cross the blood-brain… More

Metachromatic Leukodystrophy Enzyme Drug Development

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ka-wai Hui – 310-917-1275
Award Amount: $156,555.00
Abstract:
DESCRIPTION (provided by applicant): Metachromatic leukodystrophy (MLD) is an genetic disease caused by mutations in the gene encoding the lysosomal enzyme, arylsulfatase A (ASA). Symptoms including neurodegeneration and mental retardation appear during infancy or childhood; and early death can… More

Manufacturing of Trojan Horse-TNFR Decoy Receptor Fusion Protein

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ruben J. Boado – 818-252-8203
Award Amount: $981,134.00
Abstract:
DESCRIPTION (provided by applicant): Tumor necrosis factor (TNF)-alpha plays a pro-inflammatory role in aging-related neurodegenerative diseases, such as Alzheimer's disease or Parkinson's disease. The biologic TNF inhibitors (TNFI), such as the TNF decoyreceptor, cannot be developed for… More

Metachromatic Leukodystrophy Enzyme Drug Development

Award Year / Program / Phase: 2013 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ka-wai Hui – 818-252-8205
Award Amount: $999,645.00
Abstract:
DESCRIPTION (provided by applicant): Metachromatic Leukodystrophy or MLD, is a genetic disease that affects the lysosomal enzyme, arylsulfatase A (ASA). People born with MLD develop extensive lysosomal storage product accumulation in tissues, including thebrain. Children with MLD develop multiple… More